- COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
-
The invention relates to a compound of Formula I, pharmaceutical compositions comprising a compound of Formula I, and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I to
- -
-
Page/Page column 56
(2021/06/11)
-
- PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER
-
The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein ring A, R1, R3, R4, R5, and each Re have any of the values defined in the specification. Also included are novel compounds of Formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
- -
-
Page/Page column 61
(2016/03/19)
-
- BROMODOMAIN INHIBITORS
-
The present invention provides for compounds of formula (I) wherein Rx, X, Y, Y1, L1, A1, A2, A3, A4, A5, A6, A7, and A8, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
- -
-
Page/Page column 116
(2015/06/25)
-
- PYRIDINONE AND PYRIDAZINONE DERIVATIVES
-
Compounds of formula (I) wherein A1, A2, A3, A4, J, L, G, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, diabetes, obesity, cancer, and AIDS are disclosed. Pharmaceutical compositions comprising one or more compounds of formula (I) also are disclosed.
- -
-
Page/Page column 70
(2014/01/08)
-
- Pyridinone and Pyridazinone Derivatives
-
The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, J, and X3 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereo
- -
-
Paragraph 0749
(2014/01/08)
-